PGEN - The Outlook For Precigen
2025-09-23 18:18:23 ET
Shares of gene and cell therapy concern Precigen, Inc. ( PGEN ) have rallied substantially since its recurrent respiratory papillomatosis therapy Papzimeos received full approval from the FDA on August 14th. The first-ever approval for the indication will provide the company with a nine-month plus first-mover advantage over a seemingly slightly inferior candidate from Inovio Pharmaceuticals’ ( INO ) . With pricing that would suggest a large total domestic market opportunity with a market cap of just over $1 billion, Precigen merited further investigation. An analysis follows below....
The Outlook For Precigen